CANY
SLDB icon

Caxton Associates (New York)’s Solid Biosciences SLDB Stock Holding History

Caxton Associates (New York)’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,838
Closed -$311K – 683
2021
Q4 		$311K Buy
+11,838
New +$362K 0.03% 405

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Caxton Associates (New York)'s SLDB Position: Q1 2022 in Review

Caxton Associates (New York) sold out of Solid Biosciences (SLDB) in Q1 2022, closing a stake of 11,838 shares — an estimated $311K sold.

Caxton Associates (New York) first reported a position in SLDB in Q4 2021 and held it in 1 quarter. The position peaked at $311K in Q4 2021. 77 funds tracked by Wall St. Rank hold SLDB as of Q1 2022.

  • Caxton Associates (New York) reported no remaining Solid Biosciences position as of Q1 2022 after selling out during the quarter.
  • Caxton Associates (New York) sold 11,838 Solid Biosciences shares in Q1 2022, an estimated $311K.
  • Caxton Associates (New York) first reported a position in Solid Biosciences in Q4 2021 and held it in 1 quarter.
  • Caxton Associates (New York)'s Solid Biosciences position peaked at $311K in Q4 2021.
  • 77 funds tracked by Wall St. Rank held Solid Biosciences as of Q1 2022.

Based on Caxton Associates (New York)'s 13F filing for Q1 2022, filed 16 May 2022.